Syndax Pharmaceuticals INC

Syndax Pharmaceuticals announced updates on its late-stage programs and introduced new pipeline assets, including novel inhibitors for NSCLC and myelofibrosis, during its R&D event.

Syndax Pharmaceuticals has successfully issued $250 million in 2.25% convertible senior notes due 2031 to support general corporate and R&D activities.

Syndax Pharmaceuticals stockholders approved the 2026 Equity Incentive Plan and 2026 Employee Stock Purchase Plan at the 2026 Annual Meeting.

Syndax Pharmaceuticals has priced a $250 million offering of 2.25% Convertible Senior Notes due 2031 to fund general corporate purposes.

Syndax Pharmaceuticals announced robust fourth quarter and full year 2025 financial results, driven by significant growth in Revuforj and Niktimvo sales, and provided positive updates on its clinical pipeline.

Syndax Pharmaceuticals announced preliminary strong 2025 revenue for Revuforj and Niktimvo, ending the year with $394 million in cash and projecting profitability.

Syndax Pharmaceuticals, Inc. reported significant revenue growth in Q3 2025 driven by its newly commercialized products, Revuforj and Niktimvo, alongside a second FDA approval for Revuforj.

Syndax Pharmaceuticals reported significant revenue growth from its newly launched cancer therapies, Revuforj and Niktimvo, in Q2 2025, though net losses increased due to higher operating expenses.

Syndax Pharmaceuticals announces its Q1 2025 financial results, highlighting revenue growth from the successful launches of Revuforj and Niktimvo.

Syndax Pharmaceuticals reports a net loss of $84.1 million for the third quarter of 2024, while achieving a key milestone with the FDA approval of Niktimvo and advancing its revumenib program.

Syndax Pharmaceuticals reports a net loss of $140.5 million for the first half of 2024, while advancing its clinical programs for revumenib and axatilimab.

Syndax Pharmaceuticals reported a net loss of $72.4 million for the first quarter of 2024, while also highlighting progress in the development of its key drug candidates, revumenib and axatilimab.

Syndax Pharmaceuticals, a commercial-stage biopharmaceutical company, reported a net loss of $285.4 million in 2025 despite significant revenue growth from its two FDA-approved cancer therapies, Revuforj and Niktimvo.

Syndax Pharmaceuticals' 2024 10-K filing highlights commercial launches of Revuforj and Niktimvo, along with ongoing clinical development programs and financial results.

Syndax Pharmaceuticals' 10-K filing details its capital stock, anti-takeover provisions, and progress in developing cancer therapies revumenib and axatilimab.

Syndax Pharmaceuticals CEO Michael A. Metzger reported a transaction involving the sale of 32,375 shares of common stock, executed under a pre-arranged Rule 10b5-1 trading plan.

Head of R&D and CMO Nicholas A.J. Botwood exercised options and sold 65,515 shares of Syndax Pharmaceuticals common stock.

Syndax Pharmaceuticals CEO Michael A. Metzger sold 17,159 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

Syndax Pharmaceuticals' CFO, Keith A. Goldan, sold 3,410 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

Syndax Pharmaceuticals CEO Michael A. Metzger reported significant equity awards, including restricted stock units and stock options, alongside a sale to cover tax obligations.

Syndax Pharmaceuticals' CFO, Keith A. Goldan, increased his direct beneficial ownership through ESPP purchases and significant RSU and stock option grants, while also selling shares for tax obligations.

Syndax Pharmaceuticals announces its 2026 Annual Meeting of Stockholders to be held virtually on June 10, 2026.

Syndax Pharmaceuticals has filed a definitive proxy statement with the SEC.

Syndax Pharmaceuticals announces its 2025 Annual Meeting of Stockholders to be held virtually on May 14, 2025, featuring proposals for director elections, executive compensation, and auditor ratification.

Syndax Pharmaceuticals has filed a definitive proxy statement with the Securities and Exchange Commission.

Syndax Pharmaceuticals will hold its 2024 Annual Meeting of Stockholders virtually on May 15, 2024, to elect directors, vote on executive compensation, and ratify the appointment of its independent accounting firm.

Vanguard Capital Management has reported beneficial ownership of 5.05% of Syndax Pharmaceuticals Inc.'s common stock as of March 31, 2026.

The Vanguard Group reported a 0% beneficial ownership in Syndax Pharmaceuticals Inc. common stock due to an internal corporate realignment.

State Street Corporation has reported a 5.3% beneficial ownership stake in Syndax Pharmaceuticals Inc., holding 4,596,552 common shares.

The Vanguard Group filed an amended Schedule 13G, disclosing a 7.16% beneficial ownership in Syndax Pharmaceuticals Inc. common stock as of December 31, 2025.

Point72 Asset Management, along with Point72 Capital Advisors and Steven A. Cohen, has disclosed a 5.0% beneficial ownership stake in Syndax Pharmaceuticals Inc.

Point72 Asset Management, along with affiliates, has disclosed a 2.7% passive ownership stake in Syndax Pharmaceuticals Inc., holding 2,307,824 shares of common stock.